Sökning: onr:"swepub:oai:DiVA.org:uu-197813" >
A single dose of ve...
A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines
-
Erra, Elina O (författare)
-
- Askling, Helena Hervius (författare)
- Karolinska Institutet
-
- Rombo, Lars (författare)
- Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD)
-
visa fler...
-
Riutta, Jukka (författare)
-
Vene, Sirkka (författare)
-
Yoksan, Sutee (författare)
-
- Lindquist, Lars (författare)
- Karolinska Institutet
-
Pakkanen, Sari H (författare)
-
Huhtamo, Eili (författare)
-
Vapalahti, Olli (författare)
-
- Kantele, Anu (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2012-06-13
- 2012
- Engelska.
-
Ingår i: Clinical Infectious Diseases. - : Oxford University Press (OUP). - 1058-4838 .- 1537-6591. ; 55:6, s. 825-834
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND:A significant part of the world population lives in areas with endemic Japanese encephalitis (JE). For travelers from nonendemic countries, Vero cell-derived vaccine (JE-VC; Ixiaro) has replaced traditional mouse brain-derived vaccines (JE-MB) associated with safety concerns. The 2 vaccines are derived from different viral strains: JE-VC from the SA14-14-2 strain and JE-MB from the Nakayama strain. No data exist regarding whether JE-VC can be used to boost immunity after a primary series of JE-MB; therefore, a primary series of JE-VC has been recommended to all travelers regardless of previous vaccination history.METHODS:One hundred twenty travelers were divided into 4 groups: Volunteers with no prior JE vaccination received primary immunization with (group 1) JE-MB or (group 2) JE-VC, and those primed with JE-MB received a single booster dose of (group 3) JE-MB or (group 4) JE-VC. Immune responses were tested before and 4-8 weeks after vaccination using plaque reduction neutralization test (PRNT) against both vaccine strains.RESULTS:In vaccine-naive travelers, the vaccination response rate for test strains Nakayama and SA14-14-2 was 100% and 87% after primary vaccination with JE-MB and 87% and 94% after JE-VC, respectively. Antibody levels depended on the target virus, with higher titers against homologous than heterologous PRNT(50) target strain (P < .001). In travelers primed with JE-MB, vaccination response rates were 91% and 91%, and 98% and 95% after a booster dose of JE-MB or JE-VC, respectively. Subgroup analysis revealed that a higher proportion of primed (98%/95%) than nonprimed (39%/42%) volunteers responded to a single dose of JE-VC (P < .001).CONCLUSIONS:A single dose of JE-VC effectively boosted immunity in JE-MB-primed travelers. Current recommendations should be reevaluated.CLINICAL TRIALS REGISTRATION:NCT01386827.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Erra, Elina O
-
Askling, Helena ...
-
Rombo, Lars
-
Riutta, Jukka
-
Vene, Sirkka
-
Yoksan, Sutee
-
visa fler...
-
Lindquist, Lars
-
Pakkanen, Sari H
-
Huhtamo, Eili
-
Vapalahti, Olli
-
Kantele, Anu
-
visa färre...
- Artiklar i publikationen
-
Clinical Infecti ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet